| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We examined the therapeutic effects of VEGF-C156S, a lymphangiogenesis inducer, and VEGFR3-Fc, a lymphangiogenesis blocker in murine models of dilated cardiomyopathy and myocardial infarction. And we also established lymphangiogenesis factor treatments in the heart, and developed these treatments for clinical application in these murine models. In addition, we developed micro devices for clinical treatments in animal models. We have developed a method for controlling an array of cardiomyocytes. By using this technique, we examined the therapeutic effects of VEGF-C156S, a lymphangiogenesis inducer, and VEGFR3-Fc, a lymphangiogenesis blocker for application to clinical treatment strategies.
|
